APVO Aptevo Therapeutics Inc

$APVO Okay, when is an exclusivity option with big pharma going to be announced for Mipletamig and how much will the upfront payment be?

$APVO Come on, AbbVie. You know this makes all the sense in the world. Keep your billion dollar Venetoclax train moving for another decade.

$APVO The 2026 ASH abstract publication date is November, 4th 2026. It's at this point where we'll likely hear that Aptevo is scheduled to present data on Mipletamig (they can't legally mention it with the conference embargo). With SITC also happening next week, it could be a big week of news.

$APVO 🏥 Aptevo Therapeutics announced that ten patients with newly diagnosed acute myeloid leukemia advanced to allogeneic stem cell transplant after treatment with mipletamig combined with venetoclax and azacitidine. Timely market event

$APVO trispecific candidate moving toward clinical development is worth noting, manufacturing scale-up already underway

$APVO anyone paying attention to what mipletamig is actually doing for AML patients? 21% of frontline patients made it to stem cell transplant, which is meaningful bc that's considered a potentially curative option for a disease that's historically brutal to treat

$APVO can only sell about 2.3M dollars of stock through its new ATM. the filing counts its public float at about 6.9M, and a company under 75M of float can sell at most a third of it off a shelf in 12 months. holders, how do you read raising money in pieces this small: less dilution, or cash getting tight?

$APVO can sell up to about 2.3M worth of stock through its ATM with Roth as of today, the most the one-third-of-float limit allows right now. at 1.34 a share that's about 1.7M shares, almost two thirds of the 2.7M shares the public holds. a lot of supply for a float this thin. Not investment advice.

$APVO will be issued US patent number 12,760,116 tomorrow titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)"